301 results on '"Ainai, Akira"'
Search Results
2. Author Correction: Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice
3. Necroptosis in alveolar epithelial cells drives lung inflammation and injury caused by SARS-CoV-2 infection
4. Prophylactic vaccination inducing anti-Env antibodies can result in protection against HTLV-1 challenge in macaques
5. Diverse pro-inflammatory ability of mutated spike protein derived from variant strains of SARS-CoV-2
6. Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval
7. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults
8. Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization
9. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees
10. Serum anti-nucleocapsid antibody level induced after primary infection is an immunological surrogate of protection against SARS-CoV-2 re-infection in hybrid immunity holders
11. Genotyping and macrolide-resistant mutation of Bordetella pertussis in East and South-East Asia
12. Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice
13. Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire
14. Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults
15. Recombinant human thrombomodulin for pneumonia-induced severe ARDS complicated by DIC in children: a preliminary study
16. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection
17. Identification and characterization of a novel Enterococcus bacteriophage with potential to ameliorate murine colitis
18. Application of HTLV-1 tax transgenic mice for therapeutic intervention
19. Apple-shaped obesity: A risky soil for cytokine-accelerated severity in COVID-19
20. The road to a more effective influenza vaccine: Up to date studies and future prospects
21. Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus
22. An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome
23. Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in Japan
24. Estimating serum cross-neutralizing responses to SARS-CoV-2 Omicron sub-lineages elicited by pre-Omicron or Omicron breakthrough infection with exposure interval compensation modeling
25. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine
26. Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination
27. Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies
28. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults
29. Apple-shaped obesity; a risky soil for cytokine-accelerated severity in COVID-19
30. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus
31. Histological characteristics of matrix metalloproteinase‐9 and tissue inhibitor of metalloproteinases‐1 in asthmatic murine model during A(H1N1)pdm09 infection
32. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology
33. Cytokine profile of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during seasonal H1N1 infection
34. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design
35. Tuberculous pneumonia-induced severe ARDS complicated with DIC in a female child: a case of successful treatment
36. Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection
37. Analysis of bronchoalveolar lavage fluid in a mouse model of bronchial asthma and H1N1 2009 infection
38. Spi-B is critical for plasmacytoid dendritic cell function and development
39. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
40. Association Between Real-time Polymerase Chain Reaction Cycle Threshold Value and Clinical Severity in Neonates and Infants Infected With Bordetella pertussis
41. A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection
42. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
43. Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses
44. Viral and Immunological Characteristics of COVID-19 Vaccine Breakthrough Infections
45. Inhibition of the SDF-1α–CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice
46. Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers
47. Genotyping and macrolide-resistant mutation of Bordetella pertussisin East and South-East Asia
48. Evaluation of serum antibodies against SARS-CoV□2 in healthcare workers who participated in the operation of charter flights for the evacuation of Japanese residents from Hubei Province
49. Double-Stranded Structure of the Polyinosinic-Polycytidylic Acid Molecule to Elicit TLR3 Signaling and Adjuvant Activity in Murine Intranasal A(H1N1)pdm09 Influenza Vaccination
50. Enhanced airway hyperresponsiveness in asthmatic children and mice with A(H1N1)pdm09 infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.